CCELHIGH SIGNALRISK10-K

CCEL received a termination notice from Duke University ending their critical patent license agreement as of May 17, 2025, effectively blocking their planned business expansion into new therapeutic areas.

The Duke License Agreement termination represents a material blow to CCEL's growth strategy, as they can no longer expand into cerebral palsy and autism therapies through this partnership and have halted further investments in related activities. This strategic setback coincides with severe financial deterioration, including a swing from $402K profit to $2.4M loss and a dramatic decline in cash position.

Comparing 2026-02-27 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

CCEL experienced significant financial deterioration with net income swinging from a $402K profit to a $2.4M loss, while operating income collapsed 86% from $3.5M to $482K. The company dramatically reduced capital expenditures by 90% and cut R&D spending by 70%, while cash declined 43% to just $319K and stockholders' equity worsened to negative $18.6M. These metrics signal a company in financial distress that has pulled back investment spending while burning through cash reserves.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-704.2%
$402K→-$2.4M

Net income declined 704.2% — review whether driven by operations, interest costs, or non-recurring items.

Capital Expenditure
Cash Flow
-90.4%
$2.4M→$230K

Capex reduced 90.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Share Buybacks
Cash Flow
-88.1%
$1.4M→$170K

Buyback activity reduced 88.1% — capital being redeployed elsewhere or cash conservation underway.

Operating Income
P&L
-86.1%
$3.5M→$482K

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

R&D Expense
P&L
-69.7%
$1.2M→$376K

R&D spending cut 69.7% — could signal cost discipline or concerning reduction in innovation investment.

Cash & Equivalents
Balance Sheet
-43.1%
$561K→$319K

Cash declined 43.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Stockholders Equity
Balance Sheet
-40.8%
-$13.2M→-$18.6M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Inventory
Balance Sheet
-37.8%
$658K→$409K

Inventory drawn down 37.8% — strong sell-through or deliberate destocking; watch for supply constraints.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-02-28
ADDED
As of February 28, 2026, there were 8,055,150 shares of Common Stock outstanding.
As discussed further in Note 18, on February 23, 2021, the Company entered into a Patent and Technology License Agreement (the Duke License Agreement ) with Duke University ( Duke ).
Food and Drug Administration ( FDA ) approved therapies, including cerebral palsy and autism.
As discussed further in Note 18, the Company has received from Duke a notice of termination of the License Agreement as of May 17, 2025.
As of the date hereof, it is unlikely that the Company will be able to expand its business into business units (2) and (3) above through the Duke License Agreement.
+7 more — sign up free →
REMOVED
As of February 28, 2025, there were 8,082,159 shares of Common Stock outstanding.
As discussed further in Note 12, effective as of February 23, 2021, the Company entered into a Patent and Technology License Agreement (the Duke License Agreement ) with Duke University ( Duke ).
Food and Drug Administration ( FDA ) approved therapies, including cerebral palsy, autism, and multiple sclerosis.
Additionally, to support such business expansion, the Company had anticipated opening and launching its Cryo-Cell Institute for Cellular Therapies, which it initially hoped to open as early as the fourth quarter of fiscal 2021, but no later than the first quarter of fiscal 2022, but more recently reported that it anticipated opening it during the fourth quarter of fiscal 2024.
As of the date hereof, the Company can make no assurances it will be able to expand its business into business units (2) and (3) above.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →